Switch of immunosuppression from cyclosporine A to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients

Journal of Hypertension

Volumn 26, Issue 11, 2008, Pages 2213-2219

  Seckinger, Joerg ^a   Sommerer, Claudia ^a   Hinkel, Ulrich Paul ^a   Hoffmann, Oskar ^b   Zeier, Martin ^a   Schwenger, Vedat ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

Author keywords

Cyclosporine; Elasticity; Everolimus; Kidney transplantation; Mammalian target of rapamycin; Protein kinase inhibitors; Pulse pressure; Pulse wave velocity; Sirolimus; Tacrolimus

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY CYST; KIDNEY INFECTION; LEUKOCYTOSIS; LEUKOPENIA; MALE; MYALGIA; PNEUMONIA; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; STOMATITIS; ARTERY; BLOOD FLOW VELOCITY; DRUG EFFECT; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; PULSATILE FLOW;

ARTERIES; BLOOD FLOW VELOCITY; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSATILE FLOW; SIROLIMUS;

EID: 56049105634     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830ef940     Document Type: Article

References (48)

1. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 2001; 71:SS5- SS9.
2. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63:1852-1860.
3. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-670.
4. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17:1065-1072.
5. Paul LC, Sutherland F, Klassen J, Buckle S, Burgess E. Cardiovascular risk impact of cyclosporine immunosuppression in renal transplant recipients. Transplant Proc 1992; 24:2740-2741.
6. Andres V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant 2006; 21 (Suppl 3):iii14-iii17.
7. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR(-/-) mice despite severe hypercholesterolemia. Atherosclerosis 2007; 198:39-48.
8. Eisen H. Long-term cardiovascular risk in transplantation - insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3):iii9-iii13.
9. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001; 19:813-818.
10. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16:763-773.
11. Bahous SA, Stephan A, Barakat W, Blacher J, Asmar R, Safar ME. Aortic pulse wave velocity in renal transplant patients. Kidney Int 2004; 66:1486-1492.
12. Schlesselman JJ. Planning a longitudinal study. I. Sample size determination. J Chronic Dis 1973; 26:553-560.
13. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors inrenal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005; 60:249-256.
14. Asmar RG, Benetos A,Chaouche-Teyara K, Raveau-Landon CM, SafarME. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol 1993; 72:794-798.
15. O'Rourke MF. Pulse wave mechanics revisited: relevance to therapy of cardiovascular disease with calcium antagonists. Heart Vessels 1992; 7:113-122.
16. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007; 20:184-189.
17. Rehman A, Rahman AR, Rasool AH, Naing NN. The effects of angiotensin II on pulse wave velocity in healthy humans. Int J Clin Pharmacol Ther 2001; 39::423-430.
18. Santoni JP, Asmar R, Safar ME. Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension. Clin Exp Hypertens A 1989; 11 (Suppl 2):535-544.
19. Barenbrock M, Kosch M, Joster E, Kisters K, Rahn KH, Hausberg M. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20:79-84.
20. Kamar N, Mariat C, Delahousse M, Dantal J, Al Najjar A, Cassuto E, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007; : :22:1986- 1993.
21. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4:S30-S36.
22. Cohen DL, Warburton KM, Warren G, Bloom RD, Townsend R. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. Am J Hypertens 2004; 17:209-212.
23. Gelens MA, Christiaans MH, v Hooff JP. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus Transplant Proc 2005; 37:1900-1901.
24. Martinez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Seron D, Cruzado JM, et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc 2005; 37:3788-3790.
25. Iwai J, Kanayama Y, Negoro N, Okamura M, Takeda T. Gene expression of endothelin receptors in aortic cells from cyclosporine-induced hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22:404-409.
26. Wilasrusmee C, Da Silva M, Siddiqui J, Bruch D, Kittur S, Wilasrusmee S, Kittur DS. Role of endothelin-1 in microvascular dysfunction caused by cyclosporin A. J Am Coll Surg 2003; 196:584-591.
27. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Backer A, Kramer HJ. Cellular mechanisms of cyclosporine A-associated side-effects: role of endothelin. Kidney Int Suppl 1997; 61:S27-S31.
28. Goldfarb DA. Expression of TGF-beta and brogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. J Urol 2003; 169:2436-2437.
29. Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77:1661-1667.
30. Haug C, Schmid-Kotsas A, Linder T, Jehle PM, Bachem MG, Gruenert A, Rozdzinski E. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002; 103 (Suppl 48):76S-80S.
31. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004; 23:4624-4635.
32. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia- induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 2007; 100:79-87.
33. Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, Powell RJ. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004; 286:C507-C517.
34. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on antiapoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282:23679-23686.
35. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993; 55:1409-1418.
36. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Buhaescu I, Covic M. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation 2003; 76:1573-1577.
37. Zoungas S, Kerr PG, Chadban S, Muske C, Ristevski S, Atkins RC, et al. Arterial function after successful renal transplantation. Kidney Int 2004; 65:1882-1889.
38. BrietM, Bozec E, Laurent S, Fassot C, LondonGM, Jacquot C, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006; 69:350-357.
39. Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007; 18:1942-1952.
40. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001; 59:1834-1841.
41. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43:163-168.
42. Westhoff TH, Straub-Hohenbleicher H, BasdorfM, van derGiet S, Schmidt S, Offermann G, et al. Time-dependent effects of cadaveric renal transplantation on arterial compliance in patients with end-stage renal disease. Transplantation 2006; 81:1410-1414.
43. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides signicantly improved renal histology and function at 3 years. Am J Transplant 2004; 4:953-961.
44. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18:22-28.
45. Morales J, Fierro A, Benavente D, Zehnder C, Ferrario M, Contreras L, et al. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 2007; 39:591-593.
46. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007; 39:2937-2950.
47. Schwenger V, Keller T, Hofmann N, Hoffmann O, Sommerer C, Nahm AM, et al. Color Doppler indices of renal allografts depend on vascular stiffness of the transplant recipients. Am J Transplant 2006; 6:2721-2724.
48. Krumme B, Grotz W, Kirste G, Schollmeyer P, Rump LC. Determinants of intrarenal Doppler indices in stable renal allografts. J Am Soc Nephrol 1997; 8:813-816.